Key Neuroblastoma Market Players:
- Merck & Co., Inc.,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- United Therapeutics Corporation
- APEIRON Biologics AG
- Sanofi S.A.
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Y- mabs Therapeutics Inc.
- Baxter International Inc.
- Cellectar Biosciences
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of neuroblastoma is assessed at USD 438.27 million.
The global neuroblastoma market size surpassed USD 422.67 million in 2025 and is projected to witness a CAGR of over 4.1%, crossing USD 631.7 million revenue by 2035.
North America is predicted to hold a 37% revenue share by 2035 in the neuroblastoma market, owing to rising prevalence of neuroblastoma, increasing healthcare expenditure, and expanding hospital networks.
Key players in the market include Ipsen Pharma, Bachem, Chengdu Tiantaishan pharmaceutical, Ferring Pharmaceuticals, Tecnofarma SA, Dr. Reddy's Laboratories Ltd, Arbor Pharmaceutical, Inc., Teva Pharmaceutical Industries Ltd., Debiopharm International SA, Verity Pharmaceuticals Inc.
